Euroapi SAS
PAR:EAPI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (2.8), the stock would be worth €7.58 (496% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | €1.27 |
0%
|
| 3-Year Average | 2.8 | €7.58 |
+496%
|
| 5-Year Average | 3.2 | €8.59 |
+576%
|
| Industry Average | 2.1 | €5.67 |
+346%
|
| Country Average | 3 | €8.02 |
+531%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
E
|
Euroapi SAS
PAR:EAPI
|
121.1m EUR | 0.5 | -0.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 16.7 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 8.7 | 25.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.2 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 6.7 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 7 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 5.9 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 4.8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 4.2 | 19.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 4.3 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 1.7 |
| Median | 3 |
| 70th Percentile | 4.7 |
| Max | 5 681.3 |
Other Multiples
Euroapi SAS
Glance View
EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,342 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
